REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2019
14.11.2019 15:53:00 EET | Business Wire | Press release
Today, the Board of Directors of Reply [MTA, STAR: REY] approved the results as at 30 September 2019.
In the first nine months of the year, the Group has recorded a consolidated turnover of €866.2 million, which is an increase of 14.8% compared to €754.4 million at 30 September 2018.
All indicators are positive for the period (*). Consolidated EBITDA to September 2019, was €136.2 million, which is an increase of 34.6% compared to the €101.2 million recorded at September 2018. Consolidated EBITDA - excluding the effects of the application of IFRS 16 - would have been €118.4 million.
EBIT, from January to September, was €108.6 million, which is an increase of 18.9% compared to €91.4 million at September 2018). EBIT, excluding the effects of the application of IFRS 16, would have been €107.9 million.
Pre-tax profit, from January to September 2019, was €107.7 million (+11.8% compared to €96.3 million in 2018). The value excluding the effects of the application of IFRS 16 would have been equal to €108.7 million.
For the third quarter of the year, the Group’s performance is equally positive, with consolidated turnover for the period of €292.5 million, which is an increase of 14.1% compared to 2018.
EBITDA, from July to June 2019, was equal to €50.6 million (excluding the effects of the application of IFRS 16, this would have been equal to €44.8 million), with an EBIT of €41.0 million (the application of IFRS 16 does not affect EBIT ) and pre-tax profit of €37.5 million (excluding the effects of the application of IFRS 16, this would have been equal to €38.1 million).
As at 30 September 2019, the Group’s net financial position is positive at €52.9 million (€151.6 million excluding the effects of the application of IFRS 16). The net financial position as at 30 June 2019 was positive at €18.3 million.
“In the first nine months of 2019 Reply was able to achieve extremely positive results, both in terms of turnover and margins,” said Reply Chairman Mario Rizzante after the Board of Directors meeting. “Even the third quarter was characterised by significant growth, which has allowed us to view the coming months with optimism and continue with the development of our Group.”
“Reply’s strength lies in our ability to interpret digital innovation so that it meets the needs of business”, continues Mario Rizzante. “These first nine months of 2019 have seen important developments in our main offering lines: cloud, IoT and connected products, data platforms and digital experience. We have also witnessed an exponential growth in demand for new applications related to the use of artificial intelligence, an area to which Reply has long been committed and where it has acquired a leadership position.”
(*) Reply has applied the new international accounting standard IFRS 16 prospectively from 1 January 2019, which has had an effect on the value of EBITDA (+€17.8 million) and on the net financial position (-€98.7 million).
The manager responsible for preparing the company's financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries.
Reply
Reply [MTA, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new paradigms of big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005391/en/
Contact information
Media Contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Investor Relation Contacts
Reply
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594
Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom